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The ability to predict response to neoadjuvant chemotherapy for women diagnosed with breast cancer, either
before or early on in treatment, is critical to judicious patient selection and tailoring the treatment regimen. In this
paper, we investigate the role of contrast agent kinetic heterogeneity features derived from breast dynamic
contrast-enhanced magnetic resonance imaging (DCE-MRI) for predicting treatment response. We propose a set
of kinetic statistic descriptors and present preliminary results showing the discriminatory capacity of the proposed
descriptors for predicting complete and non-complete responders as assessed from pre-treatment imaging
exams. The study population consisted of 15 participants: 8 complete responders and 7 non-complete
responders. Using the proposed kinetic features, we trained a leave-one-out logistic regression classifier that
performs with an area under the receiver operating characteristic (ROC) curve (AUC) of 0.84 under the ROC. We
compare the predictive value of our features against commonly used MRI features including kinetics of the
characteristic kinetic curve (CKC), maximum peak enhancement (MPE), hotspot signal enhancement ratio (SER),
and longest tumor diameter that give lower AUCs of 0.71, 0.66, 0.64, and 0.54, respectively. Our proposed kinetic
statistics thus outperform the conventional kinetic descriptors as well as the classifier using a combination of all
the conventional descriptors (i.e., CKC, MPE, SER, and longest diameter), which gives an AUC of 0.74. These
findings suggest that heterogeneity-based DCE-MRI kinetic statistics could serve as potential imaging biomarkers
for tumor characterization and could be used to improve candidate patient selection even before the start of the
neoadjuvant treatment.
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The use of neoadjuvant chemotherapy (NAC) in women diagnosed
with breast cancer is gaining considerable acceptance [1,2]. It has
been reported that NAC gives high clinical response of up to 70% to
98% and can result in a pathologic complete response (pCR) in 3%
to 34% of patients [3–6]. On the other hand, it has also been
reported that 2% to 30% of patients may not benefit clinically or
pathologically [7]. As a result, the ability to distinguish between
highly responsive and non-responsive patients is of critical
importance for making treatment choices. Particularly, non-
responsive patients, if detected early on, can avoid unnecessary side
effects and can be routed to alternative therapies such as hormonal
treatment and/or radiation therapy [8,9]. Moreover, identifyingpotential responders can help in planning a more focused and timely
treatment regimen [5].
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clinical, and histopathologic assessment [10]. Imaging modalities
such as computed tomography (CT) and magnetic resonance imaging
(MRI) are used to assess tumor response primarily on the basis of
tumor size reduction [11–13]. A widely used criterion for therapy
response assessment is the Response Evaluation Criterion in Solid
Tumors (RECIST) [14], which uses the longest diameter of the
tumor as a basis. However, changes in tumor size due to therapy tend
to appear after at least a couple of neoadjuvant treatment cycles [1].
Therefore, response as assessed by a reduction in tumor size can cause
considerable delay in giving the appropriate treatment to partially
responsive and non-responsive patients. As a result, devising methods
for predicting early therapy response has been an active area of
research in recent years.
A review on the use of MRI for predicting response to NAC is
given in Marinovich et al. [15]. Among the work on early prediction
of therapy response, correlations between NAC response and
dynamic contrast-enhanced MRI (DCE-MRI) kinetic parameters
such as the forward and backward volume transfer coefficients (Ktrans
and kep) have been reported [16–18]. Kinetic parameters derived
from multiparametric MRI using DCE-MRI and diffusion-weighted
MRI have also been explored for assessing the response to NAC
treatment [19]. However, the changes in kinetic parameters in the
above studies have predictive value after either one or two cycles of
neoadjuvant treatment. Moreover, the estimation of volume transfer
coefficients such as K trans and kep involves a series of assumptions and
models derived from the pharmacokinetics of the contrast agent
distribution [20]. This leads to different estimates of the parameters
due to different underlying assumptions [21], making the estimates
less robust.
Hylton et al. [22] have explored morphologic and kinetic features
derived from MRI such as the measurement of tumor longest
diameter, changes in tumor volume, and peak signal enhancement
ratio (SER) in post-treatment MR images as compared to
pre-treatment images. Their analysis uses MR images acquired before
treatment as well as images obtained after first, second, and third
cycles of NAC treatment and shows that tumor volume, when
represented as a fraction of the baseline tumor volume as assessed
from pre-treatment images, has the greatest relative capacity to
monitor NAC response. Another recent method from Tateishi et al.
[23] investigates the prediction of pathologic response using positron
emission tomography (PET) and DCE-MRI parameters. They use
both the baseline imaging and images acquired after two NAC cycles.
The results of Tateishi et al. report that the sensitivity of PET CT/MR
after two cycles of NAC is not acceptable, while the specificity is high.
One of the earlier works by Rieber et al. [24] also suggested that MR
could provide information regarding response to therapy following the
first cycle. Esserman et al. assessed morphologic MR phenotypes of
tumors that correlated with NAC response [25]. However, the
detection of these phenotypes was based on subjective and visual
interpretation. Park et al. reported that pre-treatment values of mean
apparent diffusion coefficient of responders were lower than that
of non-responders [26].
The majority of the abovementioned methods are able to predict
the NAC response only after at least a couple of treatment cycles.
Among the methods that predict response based on pre-treatment
imaging, the approach of Esserman et al. [25] is based on subjectively
assessed morphologic phenotypes, while the method of Park et al.
[26] uses an aggregate measure such as the mean apparent diffusioncoefficient of the tumor. Breast tumors have been shown to be highly
heterogeneous lesions [27,28], and tumor heterogeneity is emerging
as one of the major challenges in prognostication and successful
treatment [27]. Breast cancer heterogeneity manifests in almost all
aspects of the disease including histopathologic, molecular, and
functional characteristics [28]. Traditional MRI analysis have mainly
focused on aggregate kinetic measures [29–32] or aggregate diffusion
measures [25]. However, such aggregate measures fall short of
capturing the intratumor heterogeneity that is a crucial aspect of
tumor characterization [27].
In this paper, we propose to explore heterogeneities in the contrast
uptake within a breast tumor to predict response to NAC based on
pre-treatment imaging. Our motivation to take this approach is based
on reports suggesting that aggressive tumors have heterogeneous
contrast uptake distribution perhaps due to inhomogeneous
vascularization and angiogenesis [33–35]. The conventional kinetic
descriptors either focus on aggregate kinetic measures or subsample
the tumor, making little use of the information revealed by
heterogeneities in the kinetic behavior. For instance, Bhooshan
et al. [36] derive a single characteristic kinetic curve (CKC) and
compute only one set of kinetic features from that curve. Similarly,
Loiselle et al. [37] employ the maximum peak enhancement (MPE) as
a single metric for the entire tumor. However, it has been suggested
that heterogeneities in the contrast agent uptake may reflect
important phenotypic aspects of underlying molecular intratumor
heterogeneity [38–41]. Here, we propose to tap into this potentially
rich set of information for the task of predicting response to
neoadjuvant chemotherapy.
Material and Methods
Study Population
The study population consisted of a subset of patients from the
ACRIN 6657 ISPY trial [33], imaged at our institution between 2002
and 2006. Local institutional review board (IRB) approval was
obtained before the study, and signed informed consent was obtained
from all patients before enrollment. All patients presented with
biopsy-proven T2 to T3 stage tumors of ductal carcinoma. The
patients underwent standard neoadjuvant chemotherapy, which at
the time of the study consisted of four cycles of adriamycin/cytoxan,
followed by four cycles of taxotere. Core biopsy and serum samples
were collected at comparable times to the MRI scans and obtained
pre-treatment, between 24 and 96 hours after the start of treatment,
between treatment regimens (optional), and pre-surgery. The patients
were declared as complete responders or partial responders after
evaluating pathologic response [33]. pCR was defined as no invasive
tumor present in either breast or axillary lymph nodes. The subset
population consisted of 15 patients: 8 complete responders and 7
non- complete responders.
Imaging Parameters
The imaging parameters for ISPY-1 trial have been described
before elsewhere [22]. We reproduce the imaging details for
completeness. MRI was performed with a 1.5-T imaging unit by
using a dedicated breast radiofrequency coil. Before the start of
imaging, an intravenous catheter was inserted into each patient;
patients were imaged in the prone position. The MRI protocol
included a localization acquisition and T2-weighted sequence,
followed by a DCE series. For T2-weighted imaging, a fast spin-echo
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the symptomatic breast only (two-dimensional spin echo; field of
view, 1620 cm; section thickness, 3 mm; fat saturation; echo train
length, 8 to 16; one echo; effective echo time, 80–140 milliseconds;
repetition time, 4000–6000 milliseconds). For the contrast-enhanced
series, high-spatial resolution (in-plane spatial resolution ≤ 1 mm)
three-dimensional fat-suppressed T1-weighted imaging of the
symptomatic breast was performed by using a gradient-echo sequence
with a repetition time of 20 milliseconds or less, an echo time of
4.5 milliseconds, a flip angle of 45° or less, a 16- to 18-cm field of
view, a minimum matrix of 256 × 3 × 192, and 64 sections with a
thickness of 2.5 mm or less. Imaging time for the T1-weighted
sequence ranged from 90 to 100 seconds, with one data set acquired
before injection of a gadolinium-based contrast agent and repeated at
least two times immediately after injection. The contrast agent was
administered at a dose of 0.1 mmol/kg body weight over 15 seconds,
followed by a 10-ml saline flush over 15 seconds. The resulting
temporal sampling of the center of k-space for the first contrast-
enhanced phase was between 2 minutes 15 seconds and 2 minutes
30 seconds, providing image contrast most representative of this time
point. An interphase delay between the first and the second
contrast-enhanced phase was used as needed to result in temporal
sampling of the second contrast-enhanced phase between 7 minutes
15 seconds and 7 minutes 45 seconds.
DCE-MRI Kinetic Features
For each patient, we selected the DCE-MRI exam done before the
commencement of the treatment. Lesions were segmented in a
semi-automated way by seeding an active contour snake [42].
Typically, DCE-MRI acquisition includes a pre-contrast image
(captured before the injection of a contrast agent) and a number ofFigure 1. (A) Illustration of basic kinetic featupost-contrast images, captured at different time points after the
injection of the contrast agent [43]. The uptake of the contrast agent by
different tissues manifests itself in the form of contrast enhancement in
post-contrast MR images, and the enhancement patterns have been
suggested to be useful for tumor characterization [36,43].
A commonway to quantify the enhancement pattern is to compute the
relative enhancement as compared to the pre-contrast image [44,43]. By
computing the relative enhancement on a pixel-by-pixel basis, we can
construct pixel-wise maps of the relative contrast enhancement as follows:
e u; v; tð Þ ¼ I u; v; tð Þ−I u; v; t0ð Þ
I u; v; t0ð Þ ð1Þ
where I(u, v, t) represents the intensity of pixel (u, v) captured at time t
and t0 is the pre-contrast time instant. For a particular pixel, the relative
enhancement plotted as a function of time is defined as the kinetic curve
[43]. In the literature (e.g., [44,43]), a number of basic features can be
computed from this kinetic curve as illustrated in Figure 1A. On the basis
of these features, we can derive a rich kinetic feature set by computing the
pixel-wise map for each feature as follows:
• Peak enhancement (PE):
Pe u; vð Þ ¼ max
t
E u; v; tð Þ ð2Þ
which represents the peak relative enhancement for every pixel as
computed over all post-contrast time points.
• Time to peak (T TP):
T T P u; vð Þ ¼ arg max
t
E u; v; tð Þ ð3Þ
which represents the time at which peak enhancement is achieved.res for a single pixel. (B) Pixel-wise maps.
Figure 2. Illustration of kinetic pixel partitioning for two post-contrast time points. (A) Segmented lesion, (B) set 1 pixels that achieve peak
enhancement at the first post-contrast time point (highlighted in yellow), and (C) set 2 pixels that achieve peak enhancement at the
second post-contrast time point (highlighted in green).
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WIS u; vð Þ
¼
PE u; vð Þ
T T P u; vð Þ−t0 ;
if T T P u; vð Þ≠t0
0; otherwise
8>>><
>>:
ð4Þ
which is a measure of the initial uptake rate of the contrast agent
for every pixel.
• Wash-out slope (WOS):
WOS u; vð Þ ¼
E u; v; tMð Þ−PE u; vð Þ
tM−T T P u; vð Þ ;
if tM≠T T P u; vð Þ
0; otherwise
8>>><
>>>:
ð5Þ
where tM is the last post-contrast time instant. The wash-out slope
captures the drop in the uptake rate of the contrast agent after the
peak enhancement is achieved.
Sample pixel-wise maps of above features are depicted in Figure 1B.
Kinetic Statistic Features
To capitalize fully on the richness of the abovementioned
pixel-wise kinetic feature maps, we propose to explore the contrast
agent uptake heterogeneities within each of these feature maps. We
draw our motivation from the fact that aggressive tumors tend to have
heterogeneous contrast uptake distribution due to heterogeneous
vascularization and angiogenesis [33,34]. One way to tap into the
kinetic heterogeneity of a tumor is to divide the tumor pixels into
clusters of homogeneity and look for patterns in feature statistics
within every cluster. Specifically, we propose to partition the tumor
pixels according to their kinetic behavior and compute statistics of
kinetic feature maps within these partitions.
We extract these kinetic statistics in a two-phase process: In the
first phase, the time to peak (TTP) for every pixel within the tumor is
computed. We then cluster the pixels based on their TTP values. Thisstep partitions the pixels into as many sets as the number of
post-contrast time points, i.e., set i consists of pixels that achieve their
peak enhancement at the ith post contrast time point. Figure 2
illustrates these partitions for a sample case.
In the second step, pixel-wise maps of the following features are
computed: peak enhancement (PE), wash-in slope (WIS), and
wash-out-slope (WOS) (Figure 1). On the basis of these pixel
groupings, we compute partition-wise kinetic statistics as follows: Let
M be the pixel partitioning such that Mk represents the membership
mapping of pixel k to its respective set. Given M, one can derive the
following set-wise statistics:
• Posterior probability of observing set i given the partitionM:
PðSet ¼ ijMÞ ¼ 1
N
XN
k¼1
 Mk ¼ ið Þ: ð6Þ
where δ(Mk = i) is an indicator function that equals 1 whenMk = i,
and zero otherwise. N is the total number of pixels. These N pixels
may come from an arbitrarily shaped segmentation mask specifying
the lesion.
• Mean value of feature map j for set i:
μ i; jð Þ ¼
XN
k¼1 f j kð Þ   Mk ¼ ið ÞXN
k¼1 Mk ¼ ið Þ
: ð7Þ
where fj(k) is the value of the j-th feature map for k-th pixel, and
the feature map can be any of those shown in Figure 1B.
• Variance of feature map j for set i:
σ2 i; jð Þ ¼
XN
k¼1 f j kð Þ−μ i; jð Þ
 2   Mk ¼ ið ÞXN
k¼1 Mk ¼ ið Þ
: ð8Þ
On the basis of the above definitions, m pixel partitions and n
feature maps would result into a total of m(2n + 1) features. We aim
to investigate the utility of these partition-wise kinetic statistics for
the task of predicting response to neoadjuvant chemotherapy for
breast cancer.
Table 1. Performance of Single Feature Classifiers. Column 2 Shows Feature Names Following the
Notation of Equations (6) to (8), e.g., μ(1, PE) Represents the Mean Feature Map Value of Peak
Enhancement for Set 1 Pixels. Column 3 Shows the AUC under the ROC for Each Feature
No. Feature ROC-AUC
1 P(Set = 1|M) 0.76
2 P(Set = 2|M) 0.76
3 μ(1, PE) 0.77
4 μ(2, PE) 0.81
5 σ2(1, PE) 0.78
6 σ2(2, PE) 0.73
7 μ(1, WIS) 0.77
8 μ(2, WIS) 0.81
9 σ2(1, WIS) 0.78
10 σ2(2, WIS) 0.73
11 μ(1, WOS) 0.77
12 μ(2, WOS) 0.53
13 σ2(1, WOS) 0.75
14 σ2(2, WOS) 0.54
15 Ellipticity 0.52
16 Circularity 0.51
17 Perimeter 0.53
18 Area 0.51
Figure 3. ROC comparison with standard features. The classifier
based on our proposed kinetic statistics outperforms standard
kinetic descriptors and the longest diameter that form the basis of
the RECIST criterion. The dotted blue ROC represents the case
when all the conventional features were pooled together.
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sequence was chosen as the slice for which the lesion area was
maximized. The selection of the representative slice was confirmed by a
board-certified radiologist. Given the representative slice, we computed
the kinetic statistics as defined in the Results section. For this data set,
we had two post-contrast time points, and on the basis of the TTP
values, the pixels were partitioned into two sets (m = 2). Within these
partitions, we computed statistics for three featuremaps (n = 3), i.e., PE,
WIS, and WOS. This resulted in m(2n + 1) = 14 kinetic statistics. As
DCE-MRI morphologic features (e.g., tumor size and shape) have also
been shown to be associated with different tumor grade [40], in our
feature vector we also included tumor area and perimeter to measure
tumor size and ellipticity and convexity to capture the shape of the
tumor [45,46]. Therefore, in total we had 14 kinetic features and 4
morphologic features.
Classification Experiments
To evaluate the performance of individual features, we trained a
leave-one-out single feature logistic regression classifier using each of
the features individually. Receiver operating characteristic (ROC)
analysis was performed, and the area under the ROC curve (AUC)
was computed. To evaluate the collective performance of our features,
we also trained a multivariate logistic regression classifier with
leave-one-out cross-validation. For each leave-one-out loop, we
performed sequential forward feature selection using the training
examples for the current loop, i.e., all examples but the currently left
out case. Using the selected features, a logistic regression classifier was
learned on the basis of the training set and was tested on the unseen
left out test example. The process was then repeated for all
leave-one-out loops. ROC analysis was done to assess the
performance of multivariate classifiers. To assess the importance of
features, selection frequencies of features over all cross-validation folds
were evaluated.
Comparison with Previous Work
We compare the predictive value of our features against the
following commonly used MRI features:• Kinetic features of the CKC [36,47]: On the basis of this
method, kinetic curves were computed for all the tumor pixels,
and each kinetic curve was represented as an M dimensional
vector, where M is the number of time points. Fuzzy C means
clustering was then run on theseM dimensional vectors to group
similar kinetic curves, and the centroid of each cluster was
termed as a prototype kinetic curve. The number of centroids
was selected using the same approach as Chang et al. [47], in
which the authors set the number of centroids to eitherN/160 or
2, whichever is greater, where N is the number of tumor pixels.
From among the prototype kinetic curves, the curve with the
maximum initial uptake was chosen as the CKC, and the
following kinetic features for the CKC were computed: peak
enhancement, time to peak, wash-in slope, and wash-out slope.
A leave-one-out logistic regression classifier similar to the one for
multifeature classification scheme as described above was trained.
• Hotspot SER [43]: SER at every pixel was computed as SER ¼ S1−S0S2−S0,
where S0, S1, and S2 are the signal intensities at the pre-contrast,
first post-contrast, and second post-contrast time points. A hotspot
SER value was defined as the highest eight-connected voxel average
over the tumor volume, and a leave-one-out logistic regression
classifier was trained using hotspot SER values.
• MPE [37]: Kinetic curves for all the pixels were first computed,
and the peak enhancement for each curve was evaluated. The
MPE value for each lesion was then detected and a leave-one-out
logistic regression classifier based on MPE was trained.
• Longest diameter [14]: The longest diameter of a tumor is a
standard metric that forms the basis of the RECIST [14]. A
leave-one-out logistic regression classifier was trained on the basis
of the longest diameter values.
• Pooled conventional features: Finally, we trained a classifier
model with leave-one-out feature selection by pooling all the
conventional features described in this section (i.e., CKC, SER,
MPE, and longest diameter).
Table 2. Comparison of Statistical Significance, Standard Errors, and 95% Confidence Intervals for
the AUCs Corresponding to Classification Models Based on Proposed Features and Previously
Used Standard Features
Features AUC Standard
Error
P
Value
95% Confidence Interval
Lower Bound Upper Bound
Kinetic statistics 0.84 0.088 .015 0.697 1.000
Pooled conventional features 0.72 0.125 .154 0.455 0.994
PE-CKC 0.71 0.132 .165 0.436 0.992
MPE 0.66 0.144 .355 0.332 0.954
SER 0.64 0.122 .563 0.271 0.908
Longest diameter 0.54 0.152 .728 0.243 0.864
Table 3. Selection Frequencies of Features over All Leave-One-Out Classification Loops. Column 2
Shows Feature Names Following the Notation of Equations (6) to (8), e.g., μ(1, PE) Represents the
Mean Feature Map Value of Peak Enhancement for Set 1 Pixels. Column 3 Shows the Selection
Frequency of Each Feature. Frequencies ≥50% Are Shown in Bold
No. Feature Selection Frequency (%)
1 P(Set = 1|M) 0/15 (0.0%)
2 P(Set = 2|M) 0/15 (0.0%)
3 μ(1, PE) 2/15 (13.3%)
4 μ(2, PE) 14/15 (93.3%)
5 σ2(1, PE) 12/15 (80.0%)
6 σ2(2, PE) 1/15 (6.7%)
7 μ(1, WIS) 0/15 (0.0%)
8 μ(2, WIS) 0/15 (0.0%)
9 σ2(1, WIS) 0/15 (0.0%)
10 σ2(2, WIS) 0/15 (0.0%)
11 μ(1, WOS) 12/15 (80.0%)
12 μ(2, WOS) 0/15 (0.0%)
13 σ2(1, WOS) 0/15 (0.0%)
14 σ2(2, WOS) 0/15 (0.0%)
15 Ellipticity 0/15 (0.0%)
16 Circularity 0/15 (0.0%)
17 Perimeter 0/15 (0.0%)
18 Area 0/15 (0.0%)
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AUC under ROCs for single feature classifiers are shown in Table 1.
Single feature classifiers for 12 of 14 kinetic statistics perform with
AUCs ranging from 0.73 to 0.81, while two of the kinetic features
and all the morphologic features perform close to chance. The best
single feature performance (AUC = 0.81) was given by the mean peak
enhancement for set 2 pixels, μ(2, PE). This analysis suggests that
partition-based kinetic statistics potentially possess univariate dis-
criminatory power to predict responders versus non- complete
responders from their pre-treatment images.
The ROC curve for multivariate classifier based on the proposed
features along with a comparison against previously used features is
shown in Figure 3. Classifier based on the proposed features has an
AUC of 0.84 (SE = 0.088, P = .015) under the ROC curve.
Comparison of statistical significance, standard errors, and 95%
confidence intervals for the AUCs corresponding to classification
models based on proposed features and previously used standard
features is given in Table 2. The comparison against commonly used
approaches shows that the classifier based on our proposed kinetic
statistics outperforms classifiers using conventional descriptors as well
as the classifier based on pooling all the conventional descriptors.
Selection frequencies of features over all cross-validation folds are
given in Table 3. Most frequently selected features included mean
peak enhancement for set 2 pixels, variance in peak enhancement for
set 1 pixels, and mean wash-out slope for set 1 pixels. Representative
contrast uptake patterns for the selected features along with their
corresponding box plots are shown in Figure 4. A visualization matrix
of squared correlation coefficients (R2) between features is shown in
Figure 5.
Discussion
In this paper, we have presented preliminary results showing that
heterogeneity kinetic statistics derived from DCE-MRI feature maps
(peak enhancement, wash-in slope, and wash-out slope) are
significant predictors of response to neoadjuvant chemotherapy. We
have shown that these statistics have predictive ability when derived
from a DCE-MRI exam done before the commencement of the
treatment. Most existing methods [16,1,48] become predictive after
at least two cycles of neoadjuvant treatment. The ability to predict
response before the start of the treatment can help in selecting the
patients that are expected to benefit the most from the treatment,
while routing the anticipated non-responders and partial responders
to alternative therapies. Moreover, the classifier based on our
proposed kinetic statistics outperforms the classifiers using standard
kinetic descriptors. Our proposed statistics capitalize on the
heterogeneities in the contrast agent uptake within the tumor and
the improvement is in line with studies suggesting the importance ofkinetic heterogeneities for tumor characterization [43], as they can be
potential markers of the underlying molecular intratumor heteroge-
neity [38–41].
Our results also indicate that different contrast uptake patterns exist
for completely responding and partially responding tumors, including
more pronounced enhancement, rapid washout, and heterogeneous
uptake for the responding tumors (Figure 4), suggesting a more
aggressive tumor phenotype, potentially due to higher vascularity and/
or more progressed neo-angiogenic properties. For instance, the
visualization and box plot in Figure 4A show that responding tumors
have higher values of mean peak enhancement for set 2 pixels. The
second row of Figure 4 shows that responding tumors have higher
variance in the peak enhancement of their rapidly enhancing regions
(i.e., TTP = 1). In Figure 4C, we show how washout characteristics
differ between complete responders and partial responders. Specif-
ically, responding tumors have a more steeper washout slope for their
rapidly enhancing regions. This analysis suggests that tumors with
pronounced and heterogeneous enhancement as well as rapid
washout are more likely to respond to neoadjuvant chemotherapy.
These results are in agreement with current oncologic literature
[33,34], indicating that more biologically aggressive tumors have
better response to neoadjuvant treatment.
While the majority of kinetic statistics (12 of 14) had univariate
discriminatory capacity to predict responders versus partial re-
sponders, we should note that only three were consistently selected
by the feature selection step, leading to a sparse classification model.
This is primarily due to correlations among the extracted kinetic
features. On the basis of the visualization of squared correlation
coefficients between features in Figure 5, it can be seen that there are
strong correlations between the corresponding kinetic statistics (mean and
variance) of peak enhancement andwash-in slope. Since wash-in slope is a
scalar multiple of peak enhancement (WIS = PE/TTP), it is straightfor-
ward to show that their respective statistics are also scalar multiples of each
other (i.e., μ(i, WIS) = μ(i, PE)/TTP) and σ2(i, WIS) = σ2(i, PE)/
TTP2)), and normalizing the features would lead to perfect correlations
between them as represented in Figure 5.
Compared to the kinetic features, morphologic descriptors demon-
strated poor performance. We must note, however, that morphologic
Figure 4. Representative contrast uptake patterns for the selected features. (A) Examples for pixel-wise maps of peak enhancement (PE)
for set 2 pixels (TTP = second post-contrast time point). Complete responders have higher values of PE (i.e., red), causing the mean PE
within set 2 pixels, μ(2, PE) to be higher than that of partial responders as depicted in the box plot for μ(2, PE). (B) Examples for pixel-wise
maps of PE for set 1 pixels (TTP = first post-contrast time point). Complete responders have more variance in their set 1 PE values as
depicted in the box plot for σ2(1, PE). (C) Examples for pixel-wise maps of wash-out slope (WOS) for set 1 pixels (TTP = first post-contrast
time point). Complete responders have more rapid WOS (i.e., more negative shown as blue), compared to partial responders.
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the visualization of the inter-feature correlations (Figure 5). This
perhaps highlights the point that while their information might not be
helpful for the particular task of pre-treatment therapy responseFigure 5. Visualization of the matrix of squared correlation
coefficients (R2) between features.prediction, morphologic features capture different information com-
pared to kinetic features. In this paper, we have focused on images
captured before the initiation of the treatment begins. As the treatment
progresses, changes in the morphology during the actual treatment
process, rather than the a priori imaging, can represent a measure of
response as has been explored in previous studies. Moreover, while
RECIST longest diameter is traditionally used to evaluate the response
to therapy, we also intended to investigate if tumor diameter before the
initiation of the treatment could be a predictor of response as well, and
an ROC-AUC of 0.5 suggests that it is not.
Important limitations of the current work must also be noted.
First, although promising, our analysis has been done on a relatively
small data set (15 patients), which has almost equal number of
complete responders and partial responders, whereas in a standard
NAC treatment regimen, the expected number of complete
responders is around 25% [33], and therefore larger studies are
warranted to confirm generalizability of our findings. Nevertheless,
we have employed cross-validation in our experiments to assess
generalization, and the selected features appear to be fairly consistent
across different cross-validation loops. We should note that the
temporal resolution of images used in this study is low with only three
time points (i.e., one pre-contrast and two post-contrast). However,
we would like to highlight that the proposed methodology is
independent of the temporal resolution and the number of
post-contrast time points. For future studies, images are being
captured at higher temporal resolution. In addition, the features are
Translational Oncology Vol. 8, No. 3, 2015 Breast DCE-MRI Kinetic Heterogeneity Tumor Markers Ashraf et al. 161currently extracted from a representative two-dimensional slice of the
primary lesion. Kinetic partitioning of the entire three-dimensional
volume of the lesion could potentially lead to richer statistics, especially
in the case of multifocal tumors, which may further improve the
prediction of therapy response in the future. As mentioned earlier, pCR
was assessed on the basis of no invasive cells in the excised tumor at the
time of the surgery, which is the norm for other NAC studies. However,
foci for ductal carcinoma in-situ (DCIS) might still be present, which
should be investigated in future studies. Finally, integrating proposed
imaging biomarkers with T2-weighted and diffusion-weighted imaging
as well as with tumor histopathology and molecular subtypes holds the
promise for better therapy response prediction and improved clinical
decision making for individual patients and tumor subtypes.
Conclusions
In this paper, we have investigated the role of heterogeneity kinetic
statistic features derived from breast DCE-MRI images for predicting
neoadjuvant treatment response as assessed from imaging exams done
before the treatment. We train a leave-one-out logistic regression
classifier, which when tested on unseen test cases performs with
AUC = 0.84 under the ROC curve. This analysis is based on a
leave-one out feature selection and we show that kinetic statistics
capturing the extent of contrast enhancement, uptake heterogeneity,
and washout characteristics are among consistently selected features
across cross-validation folds. We compare the predictive value of our
features against that of commonly MR features including kinetics of
CKC, hotspot SER, MPE, and longest diameter, which give lower
AUCs of 0.71, 0.66, 0.64, and 0.54, respectively. These findings
suggest that DCE-MRI heterogeneity kinetic statistics can be used
to improve candidate patient selection even before the start of the
neoadjuvant treatment. Larger studies are warranted to validate our
findings in independent populations.
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